A study [30] showed that miR-486-3p can adjust the sorafenib response in hepatocellular carcinoma (HCC), targeting both fibroblast growth factor receptor 4 (FGFR4) and epidermal growth factor (EGFR), and adjusts it to be a better treatment target than FGFR4 and EGFR inhibitors. This evidence concerns the gene FGFR4 and hepatocellular carcinoma.